Amoxicillin/clavulanic acid

Ciprofloxacin

Antibiotics

Bacteria

Escherichia coli

Cephalosporin

Biology

Microbiology

Gene

Ampicillin

Gentamicin

Tazobactam

Pseudomonas aeruginosa

Piperacillin

Clavulanic acid

Imipenem

Amoxicillin

Genetics

Medicine

Antibiotic resistance

PubMed

The increase of resistances to Escherichia coli over recent years has made it necessary to know the patterns of sensitivity in a certain area in order to be able to orient adequate empirical treatment with this knowledge.Prospective longitudinal study using E. coli isolations obtained during year 2005 in the University Hospital Virgen de la Victoria was performed. Sensitivity identification and study were made according to standardized laboratory protocols.A total of 2,612 strains of E. coli were isolated from 2,098 patients with an average age of 52 years who had urinary infection as the most frequent sign. E. coli sensitivity was: ampicillin (AMP) (35.4%), ciprofloxacin (QUIN) (67.3 %), trimethoprim-sulfametoxazole (SXT) (63.4 %), phosphomycin (97.2 %) and amoxicillin-clavulanic acid (89%). The percentage of E. coli extended-spectrum beta-lactamase (ESBL) producers was 8.2%. In general, nosocomial isolations were more resistant, this difference being significant for third generation cephalosporins, gentamicin and piperacillin/tazobactam (p < 0.005). Resistance in men was greater than in women and also in adults compared to children, with significant differences to ciprofloxacin and gentamicin (p < 0.005). A total of 27.5% of the strains were multiresistant, the most frequent phenotype being the one to AMP/SXT (11.9%), followed by AMP/QUIN/SXT (10.9%).Resistances to E. coli are very elevated in out setting, above all, in quinolones, that even appear in children, so that up to half of the multiresistant phenotypes present resistance to this family. Furthermore, during the last year, an increase in the isolations of E. coli ESBL producers has been observed.

[Distribution of patterns of sensitivity and associated phenotypes of resistance in nosocomial and community acquired Escherichia coli during 2005].